Also considered
22 papers judged, 8 emailed · Read the digest →
Phase 3 randomized trial in unresectable esophageal squamous cell carcinoma after definitive chemoradiotherapy, published in Annals of Oncology. Adding atezolizumab with or without tiragolumab did not meet the primary progression-free or overall survival endpoints versus placebo, informing decisions against routine post-chemoradiation immunotherapy in this setting.
Multicenter randomized phase 3 trial in locally advanced hepatocellular carcinoma with macrovascular invasion, comparing surgical resection versus continued maintenance therapy after induction atezolizumab plus bevacizumab, published in The Lancet. Results will inform whether adding resection to systemic immunotherapy improves outcomes in select responders, potentially changing management of advanced HCC.
Phase 3 RCT in embolisation-eligible hepatocellular carcinoma, published in Lancet Oncology. Tests adding durvalumab/tremelimumab with or without lenvatinib to TACE, potentially reshaping first-line locoregional-plus-systemic therapy for intermediate-stage HCC.
International randomized phase 2/3 trial in early- and intermediate-stage rectal cancer, published in Lancet Oncology, comparing organ-preservation strategies (chemoradiotherapy or short-course radiotherapy) versus standard surgery. Results inform whether organ-sparing approaches can safely reduce surgical morbidity without compromising oncologic outcomes, directly shaping treatment decisions in rectal cancer.
Final long-term survival update and exploratory subgroup analyses from the randomized phase II DEEPER trial comparing cetuximab- versus bevacizumab-based triplet chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer, published in JCO. No overall survival/PFS difference in the main analysis, but exploratory signals favor cetuximab in left-sided, male, and extrahepatic-disease subgroups, informing but not changing first-line treatment selection.
Extended follow-up of a phase 1b expansion cohort combining an Fc-enhanced anti-CTLA-4 antibody with an anti-PD-1 antibody in heavily pretreated microsatellite-stable metastatic colorectal cancer without liver metastases, published in Clinical Cancer Research. Shows durable responses and encouraging survival in a population traditionally resistant to immunotherapy, supporting further development of this checkpoint combination.
Pan-Asian adaptation of the ESMO clinical practice guidelines for hepatocellular carcinoma, published in ESMO Open. Provides consensus recommendations for diagnosis, treatment, and follow-up of HCC tailored to Asian populations, directly informing systemic therapy decision-making.
Multicentre phase 1b/2 trial combining the FAK inhibitor ifebemtinib with the KRASG12C inhibitor garsorasib in previously treated KRASG12C-mutated metastatic colorectal cancer, published in Lancet Oncology. Represents a novel combination strategy in a refractory population with unmet need, potentially informing future treatment approaches for KRASG12C-mutant colorectal cancer.
Phase 3 RCT in untreated, intermediate-to-high burden unresectable hepatocellular carcinoma, published in Lancet Gastroenterology & Hepatology. Evaluates adding atezolizumab-bevacizumab to on-demand TACE, informing whether combination systemic-locoregional therapy should become standard for intermediate-stage HCC.
Translational study evaluating an ultrasensitive tumor-informed ctDNA assay for detecting molecular residual disease after curative-intent therapy in locally advanced esophageal cancer, published in Clinical Cancer Research. Improved sensitivity and lead time to recurrence support its potential use in guiding postoperative surveillance and treatment decisions.
Phase Ib/II single-arm trial of a novel EGFR/c-MET bispecific antibody in heavily pretreated metastatic colorectal cancer, published in Clinical Cancer Research. Shows modest but durable responses in a molecularly selected favorable subgroup, suggesting a potential future targeted option pending further validation.
Pooled analysis of two randomized first-line trials (ARCAD database) applying a longitudinal toxicity framework to compare chronic adverse event burden of cetuximab-containing versus chemotherapy-alone regimens in metastatic colorectal cancer, published in JNCI. Offers more nuanced toxicity data (beyond worst-grade reporting) to inform patient counseling and toxicity management with cetuximab.
Substantive review in European Journal of Cancer summarizing systemic therapy options—chemotherapy, immunotherapy, targeted agents, and novel modalities—for gastroenteropancreatic neuroendocrine carcinomas. Highlights unmet needs beyond first-line platinum chemotherapy and emerging biomarker-guided approaches relevant to treatment planning.
Single-arm phase 2 trial in resectable mismatch repair-proficient and -deficient colon cancer, published in Clinical Cancer Research. Tests neoadjuvant Fc-enhanced CTLA-4 inhibitor plus PD-1 inhibitor, showing feasibility and promising pathologic response rates, including in the traditionally immunotherapy-resistant pMMR population, but requires confirmation in larger trials.
Narrative 'roadmap' review on prevention strategies for early-onset colorectal cancer, published in Nature Reviews Cancer. Synthesizes risk factors and proposes a research framework to guide future prevention efforts rather than immediate practice change.
Single-arm phase 2 trial in refractory metastatic colorectal cancer testing chemotherapy rechallenge with or without targeted agents, published in Oncology Research. Suggests adding bevacizumab or cetuximab to rechallenge chemotherapy may improve disease control over chemotherapy alone in this late-line setting.
Preclinical xenograft study in Clinical Cancer Research testing an actinium-225-labeled anti-MUC-16 radioimmunoconjugate in ovarian and pancreatic cancer models. Shows durable tumor regression in mouse models, informing future clinical development of MUC-16-targeted radioligand therapy but with no patient data yet.
Methodological analysis using pooled individual-patient data from the ARCAD metastatic colorectal cancer database to test whether synthetic external control arms can reproduce overall survival results from randomized trials, published in JNCI. Supports the feasibility of synthetic control arms for future trial design rather than directly changing current treatment decisions.
Single-arm phase 2 basket trial of T-DM1 in HER2-amplified advanced solid tumors (including lung, colorectal, and endometrial cohorts), published in Clinical Cancer Research. Shows variable response rates across tumor types, suggesting potential for HER2-directed therapy in select HER2-amplified cancers outside breast/gastric, though responses were modest in most non-salivary cohorts.
Real-world NGS cohort study comparing genomic profiles of early-onset versus average-onset metastatic colorectal cancer, published in JCO Precision Oncology. Identifies age-related differences in DNA damage repair gene alterations that are descriptive rather than directly tied to a therapeutic decision or validated outcome.
Translational study in JNCI examining epigenetic aging clocks in normal, adjacent, and tumor colorectal tissue to characterize biological aging patterns associated with carcinogenesis. Purely mechanistic/biological with no specific therapeutic decision implications for oncologists.
Retrospective cohort study in Cancer Imaging evaluating whether adding baseline SSTR-PET Krenning score to clinical/lab parameters improves survival prediction models in GEP-NET patients undergoing PRRT. Offers incremental prognostic risk-stratification tool rather than a therapy-selection biomarker.